Senate grants the FDA a 6.5% raise in funding

Share this article:
The FDA's total funding for FY 2007 has been set at $1.942 billion--representing a 6.5%
increase over the previous year. The Senate Appropriations Committee reported out the agency's spending provision as part of the agriculture appropriations bill.

The measure includes “increases of $50.5 million for pandemic avian influenza preparedness, $8.6 million for medical device and animal drug review, $4.0 million for drug safety, $5.5 million for food safety, $10.0 million for generic drug review, $5.9 million for the Critical Path initiative, and $2.5 million for human tissue safety,” a committee release said.

It noted that the bill does not include language addressing the FDA's authority to require post-marketing studies of drugs, a provision dropped by the House when it passed its version in May.

The bill does, however, include language representing a compromise agreement requiring the FDA to provide advance notification about conflicts of interest waivers granted to outside experts impaneled as “special government employees” on FDA advisory committees, 15 days prior to committee meetings.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...